Elixxer Ltd (ELXR) - Total Liabilities
Based on the latest financial reports, Elixxer Ltd (ELXR) has total liabilities worth CA$17.22 Million CAD (≈ $12.46 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Elixxer Ltd to see how much of total assets are deployed in long-term investments.
Elixxer Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Elixxer Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ELXR current and non-current assets.
Elixxer Ltd Competitors by Total Liabilities
The table below lists competitors of Elixxer Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
|
UK | GBX3.65 Million |
|
Multistack International Ltd
AU:MSI
|
Australia | AU$2.90 Million |
|
Europa Oil & Gas Holdings
LSE:EOG
|
UK | GBX6.00 Million |
|
Vaxil Bio Ltd
V:VXL
|
Canada | CA$8.00K |
|
Altair Resources Inc
V:AVX
|
Canada | CA$3.11 Million |
|
Annum Bhd
KLSE:5082
|
Malaysia | RM20.48 Million |
|
Hawkeye Gold and Diamond Inc
V:HAWK
|
Canada | CA$1.70 Million |
|
Lytus Technologies Holdings PTV. Ltd. Common Shares
NASDAQ:LYT
|
USA | $15.24 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Elixxer Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Elixxer Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 7.93 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Elixxer Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Elixxer Ltd (2017–2024)
The table below shows the annual total liabilities of Elixxer Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$15.23 Million ≈ $11.02 Million |
+22.72% |
| 2023-12-31 | CA$12.41 Million ≈ $8.98 Million |
+13.29% |
| 2022-12-31 | CA$10.95 Million ≈ $7.92 Million |
+29.54% |
| 2021-12-31 | CA$8.45 Million ≈ $6.12 Million |
-47.34% |
| 2020-12-31 | CA$16.06 Million ≈ $11.61 Million |
+424.04% |
| 2018-12-31 | CA$3.06 Million ≈ $2.22 Million |
+161.66% |
| 2017-12-31 | CA$1.17 Million ≈ $847.04K |
-- |
About Elixxer Ltd
Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. It invests in cultivation, production, and/or sale of medical cannabis and cannabis-derived products in the pharmaceutical sector. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. was incorporated in 2004 and is based in Mon… Read more